ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

CERO CERo Therapeutics Holdings Inc

1.32
-0.09 (-6.38%)
Apr 26 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 94,318
Bid Price 1.32
Ask Price 1.43
News -
Day High 1.47

Low
1.33

52 Week Range

High
12.38

Day Low 1.37
Company Name Stock Ticker Symbol Market Type
CERo Therapeutics Holdings Inc CERO NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.09 -6.38% 1.32 19:50:49
Open Price Low Price High Price Close Price Prev Close
1.42 1.37 1.47 1.37 1.41
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
514 94,318 $ 1.41 $ 132,565 - 1.33 - 12.38
Last Trade Time Type Quantity Stock Price Currency
19:57:49 16 $ 1.38 USD

CERo Therapeutics Holdings Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 19.44M - - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

CERo Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No CERO Message Board. Create One! See More Posts on CERO Message Board See More Message Board Posts

Historical CERO Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week1.521.57991.331.43122,553-0.20-13.16%
1 Month2.923.761.332.39494,362-1.60-54.79%
3 Months5.2512.381.333.101,375,040-3.93-74.86%
6 Months5.2512.381.333.101,375,040-3.93-74.86%
1 Year5.2512.381.333.101,375,040-3.93-74.86%
3 Years5.2512.381.333.101,375,040-3.93-74.86%
5 Years5.2512.381.333.101,375,040-3.93-74.86%

CERo Therapeutics Description

CERo Therapeutics Holdings, Inc. is an immunotherapy company advancing the development of engineered T cell therapeutics for the treatment of cancer. The Company¿s proprietary approach to T cell engineering, enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, which is designed to engage the body¿s full immune repertoire to achieve optimized cancer therapy. Its cellular immunotherapy platform is focused on redirecting patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating CERo, which is referred to as chimeric engulfment receptor t cells (CER-T). The Company is initiating clinical trials for its lead product candidate, CER-1236, for hematological malignancies.

Your Recent History

Delayed Upgrade Clock